Vicarius Pharma appoints new Head of Business Development

 

Vicarius Pharma is pleased to announce the appointment of Eric S. Hoffman, Ph.D. as its new Head of Business Development. Eric Hoffman brings scientific depth, Wall Street experience and extensive industry knowledge to the role. He will be based in Boston/Cambridge, MA, USA.

 

KUESSNACHT, SWITZERLAND, 13 August 2019

Vicarius Pharma AG announced today the appointment of Eric S. Hoffman, Ph.D. as its new Head of Business Development. Eric Hoffman will be based in Boston/Cambridge, MA. With this appointment, Vicarius strengthens its commitment to building strong partnerships with US-based innovator companies with late-stage specialty, rare/orphan and hospital products.

 

Before joining Vicarius Pharma, Eric Hoffman was Chief Business Officer at Genocea Biosciences for nearly four years. Prior to Genocea, he was Vice President of corporate and business development, program management and commercial operations at Idenix Pharmaceuticals, Inc. until its acquisition by Merck in August 2014. Mr. Hoffman held investor relations and business development roles at Biogen Idec from 2006 to 2010 and worked almost six years on Wall Street as an equity research analyst at J.P. Morgan, Schwab Soundview Capital Markets and BearStearns. Before starting on Wall Street in 2001, he was a post-doctoral research scientist in the Department of Immunobiology at Guy's Hospital in London, studying T cell development and cell cycle regulation. He has authored several book chapters and peer-reviewed papers, including in Cell, Immunity, and Genes & Development. He holds a Ph.D. in Immunobiology from Yale University and a B.S. in Biology from Trinity University.

 

About Vicarius

Vicarius Pharma is the premier commercial partner for innovative US-based companies seeking to commercialize late-stage specialty, rare/orphan and hospital products in Europe. The company’s executive team are experts in regulatory and pricing strategies, stakeholder/KOL management, building right-sized commercial organizations, and sustained value-creation in Europe. Vicarius’ partnering terms beat industry-standard licenses and guarantee strategic flexibility (and no poison pill) by giving our partners the right to recover their asset or to take over the commercial organization we build for them at any time. Vicarius Pharma is based in Switzerland.

 

Media Contact

 

Barbara Fry

Head Corporate Communications

Phone: +41 76 529 05 66

Email: barbara.fry@vicarius-pharma.com

 

 

 

Media

  • . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
  • . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
  • . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
  • . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
  • . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
  • . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
  •